Prophylaxis in Congenital Hemophilia with Inhibitors: The Role of Recombinant Activated Factor VII

Massimo Franchini; Franco Manzato; Gian Luca Salvagno; Martina Montagnana; Marco Zaffanello; Giuseppe Lippi

doi:10.1055/s-0029-1245114

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2009; 35(8): 814-819
DOI: 10.1055/s-0029-1245114

Prophylaxis in Congenital Hemophilia with Inhibitors: The Role of Recombinant Activated Factor VII

Massimo Franchini¹ , Franco Manzato² , Gian Luca Salvagno³ , Martina Montagnana³ , Marco Zaffanello⁴ , Giuseppe Lippi⁵

¹Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma
²Laboratorio di Patologia Clinica, Ospedale “Carlo Poma”, Mantova
³Sezione di Chimica Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona
⁴Dipartimento Materno-Infantile e di Biologia Genetica; Verona
⁵Unità Operativa di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma; Italy

Abstract

ABSTRACT

The development of inhibitors against therapeutically administered factors VIII or IX is actually the most challenging complication of hemophilia patients with inhibitors. The introduction of bypassing agents (i.e., activated prothrombin complex concentrates and recombinant activated factor VII [rFVIIa]) has dramatically improved the management of bleeding episodes in such patients. Over the last decade, there have been increasing reports on the ability of bypassing agents to prevent surgical, joint, or other bleeds in inhibitor patients. The published data on the use of rFVIIa as a prophylactic treatment in hemophilia patients with inhibitors are reviewed in this article.

KEYWORDS

rFVIIa - prophylaxis - surgery - bleeding

Volltext

Referenzen

REFERENCES

1 Haya S, Moret A, Cid A R et al.. Inhibitors in haemophilia A: current management and open issues. Haemophilia. 2007; 13(Suppl 5) 52-60
2 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4) 418-435
3 Lee C A, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost. 2006; 32(Suppl 2) 10-14
4 DiMichele D M, Hoots W K, Pipe S W, Rivard G E, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; (13 Suppl 1) 1-22
5 DiMichele D M, Kroner B L. North American Immune Tolerance Study Group . The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002; 87(1) 52-57
6 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005; 93(6) 1027-1035
7 Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9(4) 464-520
8 Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost. 1999; 82(2) 531-539
9 Leissinger C A. Prophylaxis in haemophilia patients with inhibitors. Haemophilia. 2006; 12(Suppl 6) 67-73
10 Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002; 42(1) 114-124
11 Hedner U, Glazer S, Pinkel K et al.. Successful use of rFVIIa in a patient with severe haemophilia A during synovectomy. Lancet. 1988; 2 1193
12 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004; 2(6) 899-909
13 Shapiro A D, Gilchrist G S, Hoots W K, Cooper H A, Gastineau D A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998; 80(5) 773-778
14 Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998; 9(2) 119-128
15 Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999; 5(4) 253-259
16 Ingerslev J, Freidman D, Gastineau D et al.. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis. 1996; 26(Suppl 1) 118-123
17 DiMichele D. The use of recombinant factor VIIa (Novoseven) for central catheter insertion: an international experience. Thromb Haemost. 1997; 22(suppl) 167-172
18 Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000; 26(4) 425-432
19 Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi F A, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost. 2001; 86(4) 954-958
20 Smith M P, Ludlam C A, Collins P W et al.. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost. 2001; 86(4) 949-953
21 Ludlam C A, Smith M P, Morfini M, Gringeri A, Santagostino E, Savidge G F. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. 2003; 120(5) 808-813
22 Pruthi R K, Mathew P, Valentino L A et al.. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost. 2007; 98(4) 726-732
23 Laurian Y D, Tagariello G, Jimenez-Yuste V et al.. Primary knee arthroplasty using recombinant factor VIIa (rFVIIa) as first-line therapy in haemophilia patients with high responding inhibitors. J Thromb Haemost. 2007; 5(Suppl 2) , Abstract PM140
24 Rodriguez-Merchan E C, Hedner U, Heijnen L et al.. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia. 2008; 14(Suppl 6) 68-81
25 Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia. 2008; 14(Suppl 3) 196-201
26 Goldstein B, Geldziler B, Bjerre J, Seremetis S. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents. Transfus Apher Sci. 2008; 38 25-32
27 Hedner U. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia. 2008; 14(Suppl 6) 23-27
28 Brackmann H H, Effenberger E, Hess L, Schwaab R, Oldenburg J. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis. 2000; 11(11 Suppl 1) S39-44
29 Saxon B R, Shanks D, Jory C B, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost. 2001; 86 1126-1127
30 Cooper H A, Jones C P, Campion E, Roberts H R, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia. 2001; 7(5) 517-522
31 Bryant P, Carr M, Martin E, Sutton J. High dose recombinant activated factor VII in a pediatric patient with factor VIII deficiency and high titer inhibitor. , [abstract] Blood. 2003; 102 104b-105b
32 Young G, McDaniel M, Nugent D J. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia. 2005; 11(3) 203-207
33 Morfini M, Auerswald G, Kobelt R A et al.. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia. 2007; 13(5) 502-507
34 Konkle B A, Ebbesen L S, Erhardtsen E et al.. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007; 5(9) 1904-1913
35 Hoots W K, Ebbesen L S, Konkle B A Novoseven (F7HAEM-1505) Investigators et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008; 14(3) 466-475
36 Marques-Verdier A, Chaleteix C, Souliè B, Bay J O. Secondary prophylaxis with recombinant activated factor VII (RFVIIA) in a severe haemophilia A patient with anti-factor VIII inhibitors. J Thromb Haemost. 2007; 5(Suppl 2) , Abstract PT168
37 Lopez Fernandez M, Saavedra A, Amor Otero M A, Batlle J. Primari prophylactic treatment with recombinant activated factor VII (RFVIIA) during immune tolerance in a haemophilic child. J Thromb Haemost. 2007; 5(Suppl 2) , Abstract PT161
38 Blatny J, Kohlerova S, Zapletal O, Fiamoli V, Penka M. RFVIIA is effective alternative to APCC in prophylaxis of bleeding during immune tolerance protocol in haemophiliac with inhibitor. J Thromb Haemost. 2007; 5(Suppl 2) , Abstract PT166
39 Jimenez-Yuste V, Quintana M, Alvarez M T, Martin-Salces M, Hernandez-Navarro F. “Primary prophylaxis” with rFVIIa in a patient with severe haemophilia A and inhibitor. Blood Coagul Fibrinolysis. 2008; 19(7) 719-720
40 Brophy D F, Martin E J, Nolte M E, Kuhn J G, Carr Jr M E. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia. 2007; 13(5) 533-541
41 Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost. 2009; 7(2) 299-305

Dr. Massimo FranchiniM.D.

Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio

Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

eMail: massimo.franchini@azosp.vr.it